For example, RUNX3 was shown to enhance tumorigenesis in acute myeloid leukemia [14,15], T-cell acute lymphoblastic lymphoma [16], natural killer/T-cell lymphoma [17], myelodysplastic syndrome [18], skin [19,20], head and neck [21,22], ovarian [23,24,25,26], and pancreatic [27] cancers, and Ewing’s sarcoma [28]. This evidence concerns the gene RUNX3 and cancer.